Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash from Operations over the past 9 years, most recently at 92901000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 38.93% year-over-year to 92901000.0; the TTM value through Dec 2025 reached 377922000.0, down 64.18%, while the annual FY2025 figure was 377922000.0, 64.18% down from the prior year.
  • Cash from Operations for Q4 2025 was 92901000.0 at Crinetics Pharmaceuticals, up from 110718000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 13543000.0 in Q1 2022 and troughed at 110718000.0 in Q3 2025.
  • A 5-year average of 49025350.0 and a median of 41072500.0 in 2023 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: surged 32.51% in 2022 and later tumbled 200.66% in 2023.
  • Year by year, Cash from Operations stood at 22899000.0 in 2021, then plummeted by 53.75% to 35207000.0 in 2022, then decreased by 15.9% to 40806000.0 in 2023, then plummeted by 63.88% to 66871000.0 in 2024, then tumbled by 38.93% to 92901000.0 in 2025.
  • Business Quant data shows Cash from Operations for CRNX at 92901000.0 in Q4 2025, 110718000.0 in Q3 2025, and 85851000.0 in Q2 2025.